Suppr超能文献

癌症老年患者对接受 COVID-19 二价疫苗加强针的意愿:中国四个省份的分层分析。

Willingness to receive the second booster of COVID-19 vaccine among older adults with cancer: a stratified analysis in four provinces of China.

机构信息

Clinical Research Academy, Peking University Shenzhen Hospital, Shenzhen, China.

Department of Epidemiology, China Medical University, Shenyang, Liaoning, China.

出版信息

Front Public Health. 2024 Feb 22;12:1298070. doi: 10.3389/fpubh.2024.1298070. eCollection 2024.

Abstract

BACKGROUND

Despite the elevated COVID-19 risk for older adults with cancer, vaccine hesitancy poses a significant barrier to their immunization. Intriguingly, there is limited research on the prevalence of willingness to receive the second booster dose and associated determinants in older adults with cancer.

OBJECTIVE

Our objective was to ascertain the level of awareness about COVID-19 vaccines and to uncover the factors influencing the willingness to receive the second booster among Chinese cancer patients aged 65 years and over.

METHODS

To achieve our objective, we conducted a multicenter cross-sectional study in four tertiary hospitals from four provinces of China. This involved using a Health Belief Model (HBM) based self-administered questionnaire and medical records. Subsequently, we employed multivariable logistic regression to identify factors influencing the second COVID-19 booster vaccine willingness.

RESULTS

Our results showed that among 893 eligible participants, 279 (31.24%) were aged 65 years and over, and 614 (68.76%) were younger. Interestingly, the willingness to receive the second COVID-19 booster vaccine was 34.1% (95/279) (OR: 1.043, 95% CI: 0.858, 1.267) in participants aged 65 years and over, which was similar to participants aged under 65 years (34.1% vs. 35.5%,  = 0.673). Furthermore, our findings revealed that a positive attitude toward the booster and recommendations from healthcare providers and family members were positively associated with vaccine willingness. Conversely, perceptions of negative impacts on cancer control and vaccine accessibility regarding the second COVID-19 booster were inversely related to the outcome event (all  < 0.05).

CONCLUSION

Our study concludes with the finding of a low willingness toward the second COVID-19 booster in Chinese cancer patients, particularly in the older adults, a fact which warrants attention. This reluctance raises their risk of infection and potential for severe outcomes. Consequently, we recommend using media and community outreach to dispel misconceptions, promote the booster's benefits, and encourage vaccine discussions with healthcare providers and family members.

摘要

背景

尽管患有癌症的老年人感染 COVID-19 的风险较高,但疫苗犹豫仍是他们接种疫苗的重大障碍。有趣的是,针对癌症老年患者接种第二剂加强针的意愿及其相关决定因素,相关研究十分有限。

目的

本研究旨在了解中国老年癌症患者对 COVID-19 疫苗的认知程度,并探讨影响其接种第二剂加强针意愿的因素。

方法

我们在中国四个省份的四家三级医院开展了一项多中心横断面研究。研究采用基于健康信念模型(HBM)的自我管理问卷和病历。随后,我们采用多变量逻辑回归分析来确定影响第二剂 COVID-19 加强针疫苗接种意愿的因素。

结果

在 893 名符合条件的参与者中,279 名(31.24%)年龄在 65 岁及以上,614 名(68.76%)年龄在 65 岁以下。有趣的是,65 岁及以上参与者愿意接种第二剂 COVID-19 加强针的比例为 34.1%(95/279)(OR:1.043,95%CI:0.858,1.267),与 65 岁以下参与者相似(34.1% vs. 35.5%,  = 0.673)。此外,我们的研究结果表明,对加强针的积极态度以及来自医疗保健提供者和家庭成员的建议与疫苗接种意愿呈正相关。相反,对第二剂 COVID-19 加强针可能对癌症控制和疫苗可及性产生负面影响的看法与结果事件呈负相关(均  < 0.05)。

结论

我们的研究发现,中国癌症患者,特别是老年患者对第二剂 COVID-19 加强针的意愿较低,这一点值得关注。这种不情愿使他们面临感染和严重后果的风险增加。因此,我们建议利用媒体和社区外联活动来消除误解,宣传加强针的益处,并鼓励与医疗保健提供者和家庭成员讨论疫苗接种。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9958/10917962/6cbbe177eee2/fpubh-12-1298070-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验